From the Research
When monitoring a patient receiving Meropenem (Merrem) intravenously, healthcare providers should prioritize assessing renal function through serum creatinine and BUN levels, as the drug requires dose adjustment in renal impairment, according to the most recent study 1.
Key Monitoring Parameters
- Renal function: serum creatinine and BUN levels to adjust dosage in renal impairment
- Complete blood counts: to detect potential hematologic effects like neutropenia or thrombocytopenia
- Liver function tests: to identify any hepatotoxicity
- Clinical response: through vital signs, white blood cell counts, and improvement in infection symptoms
- Hypersensitivity reactions: especially during the first dose, which may manifest as rash, urticaria, or anaphylaxis
- Seizures: a rare but serious side effect, particularly in patients with CNS disorders or renal impairment
- Superinfections: like Clostridioides difficile-associated diarrhea
- Electrolyte imbalances: to ensure proper balance
- Injection site: for phlebitis or extravasation The most recent study 1 highlights the importance of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients, making renal function monitoring crucial.
Additional Considerations
- Meropenem is a broad-spectrum carbapenem antibiotic that works by inhibiting bacterial cell wall synthesis
- Dose adjustment is necessary in patients with renal insufficiency, as shown in studies 2, 3, and 4
- Continuous renal replacement therapy (CRRT) affects meropenem clearance, as noted in study 5 By prioritizing these monitoring parameters and considering the patient's renal function, healthcare providers can ensure safe and effective therapy with meropenem.